{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.4"}]}],"title":"Week 24 Mental Score (n = 1850)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4"}]}],"title":"Week 48 Mental Score (n = 1789)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3"}]}],"title":"Week 108 Mental Score (n = 1551)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.1"}]}],"title":"Week 156 Mental Score (n = 1468)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1"}]}],"title":"Week 204 Mental Score (n = 1377)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9"}]}],"title":"Week 264 Mental Score (n = 1302)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2"}]}],"title":"Week 24 Physical Score (n = 1850)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4"}]}],"title":"Week 48 Physical Score (n = 1789)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2"}]}],"title":"Week 108 Physical Score (n = 1551)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5"}]}],"title":"Week 156 Physical Score (n = 1468)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1"}]}],"title":"Week 204 Physical Score (n = 1377)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.7"}]}],"title":"Week 264 Physical Score (n = 1302)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"The SF-36 Health Survey uses participant-reported symptoms on 8 subscales to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100 with a higher score indicating better HRQoL. A clinically relevant improvement in the Physical and Mental Component Scores of the SF-36 was defined as a ≥ 5-point increase from Baseline.","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"NUMBER","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.","timeFrame":"Baseline to Week 264","title":"Percentage of Participants With a Clinically Relevant Improvement in the Physical and Mental Component Scores of the Short Form 36 (SF-36) Health Survey at Weeks 24, 48, 108, 156, 204, and 264","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}